Telix Pharmaceuticals
TLX
40 hedge funds and large institutions have $8.47M invested in Telix Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 4 closing their positions.
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
48% more funds holding
Funds holding: 27 → 40 (+13)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
8% more capital invested
Capital invested by funds: $7.88M → $8.47M (+$591K)
0.09% more ownership
Funds ownership: 0.24% → 0.33% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIC
Portland Investment Counsel
Burlington,
Ontario, Canada
|
+$1.33M |
| 2 |
Lazard Asset Management
New York
|
+$1.31M |
| 3 |
JP Morgan Chase
New York
|
+$472K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$354K |
| 5 |
Mariner
Overland Park,
Kansas
|
+$352K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.7M |
| 2 |
Jane Street
New York
|
-$317K |
| 3 |
HF
HRT Financial
New York
|
-$111K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$34.7K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$18.4K |
TLX Hedge Fund Activity: Q4 2025 in Review
40 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q4 2025, worth a combined $8.47M — up 7.5% from $7.88M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TLX positions and 4 closed out — a net gain of 13 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Portland Investment Counsel, adding an estimated $1.33M. The largest seller was Millennium Management, cutting an estimated $1.7M.
- 40 institutional investors held Telix Pharmaceuticals (TLX) as of Q4 2025, up from 27 in Q3 2025.
- Funds reported $8.47M of Telix Pharmaceuticals stock for Q4 2025, up 7.5% quarter-over-quarter.
- 17 funds opened new Telix Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +13 holders.
- The largest Telix Pharmaceuticals buyer in Q4 2025 was Portland Investment Counsel, an estimated $1.33M added.
- The largest Telix Pharmaceuticals seller in Q4 2025 was Millennium Management, an estimated $1.7M sold.
Based on aggregated 13F filings for Q4 2025.